{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-031624","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.401712+00:00","generated_at":"2026-05-23T15:52:32.795820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share","bullets":["Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.","Loss from operations of $1.9M vs income of $3.5M in 2023.","Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.","Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.","Management expects 2025 net revenues to reach or exceed 2024 levels."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-031624","json":"https://secwatch.observer/filing/0001213900-25-031624.json","markdown":"https://secwatch.observer/filing/0001213900-25-031624.md","text":"https://secwatch.observer/filing/0001213900-25-031624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/0001213900-25-031624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/ea0237926-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:52:32.795820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}